FDA Approves Low-Cost HIV Prevention Shot, Enabling Generic Production
What happened
The Food and Drug Administration approved a low-cost version of a twice-yearly HIV prevention shot. Gilead Sciences, the original developer, granted licenses for the drug. Dr Reddy’s Laboratories, the generic manufacturer, announced the approval, noting the generic will be available for $40 per person per year in 120 countries.
From jamaicaobserver.com
Why it matters
The approval brings the breakthrough drug closer to market access in low-income countries. The pricing agreement, established in September 2025, allows for affordable global distribution of the long-acting injectable.
From jamaicaobserver.com
Who's involved
- Food and Drug AdministrationApproved the low-cost version of the HIV prevention shot.
- Gilead SciencesDeveloped the original HIV prevention shot.
- Clinton Health Access InitiativeParticipated in the pricing agreement for the generic drug.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Gilead SciencesSpeculative
Gilead Sciences might see a shift in revenue structure as generic production is licensed for low-cost global access.
- Clinton Health Access InitiativeSpeculative
Clinton Health Access Initiative could see its business participation benefit from the successful pricing agreement.
Keep exploring
The entities involved
-
Food and Drug Administration
government organization in Nonthaburi, Thailand